Get to know our clinical trials
Clinical trial to compare iberdomide maintenance therapy versus lenalidomide maintenance therapy after autologous stem cell transplantation (ASCT) in participants with newly diagnosed multiple myeloma (MMND).
THE PURPOSE OF THIS STUDY IS TO BETTER UNDERSTAND HOW AN INVESTIGATIONAL DRUG CALLED IBERDOMIDE (ALSO KNOWN AS BMS-986382 OR CC-220) WORKS TO TREAT MULTIPLE MYELOMA, COMPARED TO LENALIDOMIDE (ALSO KNOWN AS REVLIMID®), AFTER YOU HAVE UNDERGONE AN AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) AND RECOVERED, AND YOUR DOCTOR FEELS IT IS APPROPRIATE TO CONTINUE TREATMENT TO KEEP YOUR MYELOMA UNDER CONTROL. THIS IS ALSO CALLED MAINTENANCE TREATMENT.
Technical Summary
- PHASE III, TWO-STAGE, RANDOMIZED, MULTICENTER, CONTROLLED, OPEN-LABEL, PHASE III STUDY TO COMPARE IBERDOMIDE MAINTENANCE THERAPY VERSUS LENALIDOMIDE MAINTENANCE THERAPY AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN PARTICIPANTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (MMND) (EXCALIBER MAINTENANCE)
- Code EudraCT: 2022-501515-14-00
- Protocol number: IM048-022
- Promoter: Celgene Corporation
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.